BRAF and melanoma: According to a pooled analysis of data from three trials (KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006) that included 1558 patients with advanced melanoma (42.2% of patients were 65 years or older), the majority of patients ≥ 65 years had BRAF wild-type melanoma rather than BRAF V600 mutant melanoma (83.9% versus 16.1%) [54].